Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03038100 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,301
- Enrollment target
- 20
- Study locations
NCT03038100: Completed Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Hoffmann-La Roche.
NCT03038100 is a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer that has completed, run by Hoffmann-La Roche. The registered enrollment target is 1,301 participants, above the 725-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03038100, a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,301 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.
Primary Outcome
Investigator-assessed PFS is defined as the time from randomization to the occurrence of disease progression, as determined by the investigator from tumor assessments per RECIST v1.1, or death from any cause during the study, whichever occurs first.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Paclitaxel
- DRUG Atezolizumab Placebo
Study Locations (20)
California
- Moores Cancer Center at UC San Diego Health - La Jolla
- LAC + USC Medical Center - Los Angeles
- UCLA - School of Medicine - Los Angeles
- Kaiser Permanente - Oakland - Oakland
- The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange - Orange
- UC Irvine Medical Center - Orange
- Stanford University - Palo Alto
- Kaiser Permanente - Sacramento - Roseville
- Southern California Kaiser Permanente - San Diego
- California Pacific Medical Center Research Institute - San Francisco
- K. Permanente - San Fransisco - San Francisco
- University of California San Francisco Cancer Center - San Francisco
- Kaiser Permanente - Santa Clara - Santa Clara
- Olive View/Ucla Medical Center - Sylmar
- Kaiser Permanente - Walnut Creek - Walnut Creek
Arizona
- St. Joseph'S Hospital & Medical Center - Phoenix
- Arizona Oncology Associates, PC - HAL - Scottsdale
- Arizona Oncology - HOPE Wilmot - Tucson
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion - Aurora
Connecticut
- Danbury Hospital - Danbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,301 participants |
| Start Date | 2017-03-08 |
| Est. Completion | 2022-08-12 |
| Phase | Phase 3 |
What the finished NCT03038100 record still lists
NCT03038100 is an interventional study that assigns participants to a tested intervention. Its 1,301 participants enrollment target places it among the larger protocols in the corpus, above the 725-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% higher).
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT03038100 names 20 study sites across 4 states, led by California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT03038100 about?
NCT03038100 is a clinical study titled "A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tub...
What is the current status of trial NCT03038100?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,301 participants. The study started on 2017-03-08. Estimated completion is 2022-08-12.
What conditions does trial NCT03038100 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms.
What interventions are being tested in trial NCT03038100?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Atezolizumab (DRUG), Paclitaxel (DRUG), Atezolizumab Placebo (DRUG).
Who is sponsoring clinical trial NCT03038100?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03038100 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03038100's enrollment target sits among peer trials
1,301 20th of 322 higher than 303 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
- NCT04792684 · 1,300 participants
Collection of Samples USOPTIVAL Study
- NCT05166694 · 1,300 participants · NA
Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
- NCT05282654 · 1,300 participants · NA
Real-time Symptom Monitoring Using ePROs to Prevent Adverse Events During Care Transitions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI